A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Latest Information Update: 25 Mar 2021
At a glance
- Drugs ABBV-744 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 22 Mar 2021 Status changed from recruiting to discontinued.
- 05 Jun 2020 Planned number of patients changed from 40 to 100.
- 05 Jun 2020 Planned primary completion date changed from 28 Jul 2021 to 14 Jan 2022.